PACIRA BIOSCIENCES, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 26.33 USD | +3.25% |
|
+0.30% | -21.96% |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 1,890 | 2,600 | 2,680 | 1,772 | 1,567 | 1,225 | - | - |
| Enterprise Value (EV) 1 | 2,118 | 2,962 | 3,144 | 2,357 | 1,811 | 1,309 | 1,106 | 1,004 |
| P/E ratio | -168 x | 18 x | 65.4 x | 114 x | 37.9 x | 21.5 x | 13.5 x | 9.61 x |
| Yield | - | - | - | - | - | - | - | - |
| Capitalization / Revenue | 4.49 x | 6.05 x | 4.95 x | 2.66 x | 2.32 x | 1.77 x | 1.6 x | 1.47 x |
| EV / Revenue | 5.03 x | 6.89 x | 5.81 x | 3.53 x | 2.68 x | 1.89 x | 1.45 x | 1.2 x |
| EV / EBITDA | 22.3 x | 26.3 x | 15.4 x | 11.1 x | 8.44 x | 6.01 x | 4.09 x | 2.99 x |
| EV / FCF | 30.5 x | 40.6 x | 39.4 x | 20.5 x | 13 x | 7.24 x | 5.31 x | 3.87 x |
| FCF Yield | 3.28% | 2.47% | 2.54% | 4.89% | 7.7% | 13.8% | 18.8% | 25.9% |
| Price to Book | 5.35 x | 4.21 x | 3.69 x | 2.29 x | - | 1.38 x | 1.21 x | 0.98 x |
| Nbr of stocks (in thousands) | 41,731 | 43,444 | 44,544 | 45,882 | 46,438 | 46,523 | - | - |
| Reference price 2 | 45.30 | 59.84 | 60.17 | 38.61 | 33.74 | 26.33 | 26.33 | 26.33 |
| Announcement Date | 2/20/20 | 2/25/21 | 2/24/22 | 2/28/23 | 2/29/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 421 | 429.6 | 541.5 | 666.8 | 675 | 693.6 | 764.4 | 833.3 |
| EBITDA 1 | 94.86 | 112.6 | 204 | 212.7 | 214.5 | 217.7 | 270.5 | 336.1 |
| EBIT 1 | 75.28 | 99.3 | 189.2 | 194.8 | 197.7 | 195.1 | 244.3 | 295.3 |
| Operating Margin | 17.88% | 23.11% | 34.94% | 29.21% | 29.28% | 28.13% | 31.96% | 35.44% |
| Earnings before Tax (EBT) 1 | -10.75 | 20.09 | 56.4 | 13.3 | 61.7 | 84.49 | 122.9 | 147 |
| Net income 1 | -11.02 | 145.5 | 41.98 | 15.91 | 41.96 | 60.38 | 91.2 | 114.8 |
| Net margin | -2.62% | 33.87% | 7.75% | 2.39% | 6.22% | 8.71% | 11.93% | 13.77% |
| EPS 2 | -0.2700 | 3.330 | 0.9200 | 0.3400 | 0.8900 | 1.224 | 1.943 | 2.740 |
| Free Cash Flow 1 | 69.5 | 73.03 | 79.85 | 115.2 | 139.5 | 180.9 | 208.1 | 259.6 |
| FCF margin | 16.51% | 17% | 14.75% | 17.28% | 20.67% | 26.08% | 27.23% | 31.16% |
| FCF Conversion (EBITDA) | 73.27% | 64.87% | 39.14% | 54.15% | 65.03% | 83.07% | 76.93% | 77.26% |
| FCF Conversion (Net income) | - | 50.18% | 190.21% | 724.11% | 332.47% | 299.55% | 228.2% | 226.21% |
| Dividend per Share | - | - | - | - | - | - | - | - |
| Announcement Date | 2/20/20 | 2/25/21 | 2/24/22 | 2/28/23 | 2/29/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q3 | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 127.7 | 159.2 | 158 | 169.4 | 167.5 | 172 | 160.3 | 169.5 | 163.9 | 181.2 | 166.3 | 173.4 | 172.3 | 182.8 | 189.1 |
| EBITDA 1 | 48.14 | 69.34 | 53.83 | 44.92 | 55.23 | 58.77 | 41.9 | 54.26 | 52.94 | 65.39 | 46.2 | 52.81 | 51.28 | 60.75 | 61.8 |
| EBIT 1 | 44.42 | 63.99 | 49.17 | 40.9 | 50.76 | 53.96 | 37.44 | 50.27 | 49.25 | 60.71 | 43.57 | 48.79 | 46.16 | 55.02 | 59.2 |
| Operating Margin | 34.78% | 40.2% | 31.12% | 24.14% | 30.31% | 31.38% | 23.35% | 29.66% | 30.04% | 33.5% | 26.2% | 28.15% | 26.79% | 30.11% | 31.3% |
| Earnings before Tax (EBT) 1 | 24.23 | -6.197 | 7.294 | 22.01 | 2.069 | -18.07 | -26.47 | 37.85 | 16.6 | 33.72 | 20.47 | 23.06 | 20.25 | 20.72 | 27.5 |
| Net income 1 | 17.66 | -5.129 | 6.828 | 19.88 | -0.693 | -10.1 | -19.54 | 25.76 | 10.86 | 24.87 | 13.69 | 16.15 | 14.16 | 16.38 | 20.62 |
| Net margin | 13.83% | -3.22% | 4.32% | 11.73% | -0.41% | -5.87% | -12.18% | 15.2% | 6.62% | 13.72% | 8.23% | 9.31% | 8.22% | 8.96% | 10.9% |
| EPS 2 | 0.3900 | -0.1200 | 0.1500 | 0.4000 | -0.0200 | -0.2200 | -0.4300 | 0.5100 | 0.2300 | 0.5000 | 0.2425 | 0.3100 | 0.2700 | 0.3650 | 0.3800 |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 11/3/21 | 2/24/22 | 5/4/22 | 8/3/22 | 11/3/22 | 2/28/23 | 5/3/23 | 8/2/23 | 11/2/23 | 2/29/24 | - | - | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt 1 | 228 | 363 | 464 | 585 | 244 | 83.9 | - | - |
| Net Cash position 1 | - | - | - | - | - | - | 119 | 221 |
| Leverage (Debt/EBITDA) | 2.402 x | 3.222 x | 2.273 x | 2.751 x | 1.137 x | 0.3856 x | - | - |
| Free Cash Flow 1 | 69.5 | 73 | 79.9 | 115 | 139 | 181 | 208 | 260 |
| ROE (net income / shareholders' equity) | 20.9% | 19.8% | 20.2% | 16% | - | 11% | 12.2% | 16.6% |
| ROA (Net income/ Total Assets) | 9.3% | 9.17% | 8.16% | 6.43% | - | 6.27% | 7.71% | 10.5% |
| Assets 1 | -118.5 | 1,586 | 514.5 | 247.5 | - | 962.9 | 1,183 | 1,092 |
| Book Value Per Share 2 | 8.470 | 14.20 | 16.30 | 16.90 | - | 19.00 | 21.80 | 26.90 |
| Cash Flow per Share | - | - | - | - | - | - | - | - |
| Capex 1 | 10.2 | 37.8 | 45.9 | 30.1 | 15.2 | 17 | 22.8 | 25 |
| Capex / Sales | 2.41% | 8.8% | 8.47% | 4.51% | 2.25% | 2.45% | 2.99% | 3% |
| Announcement Date | 2/20/20 | 2/25/21 | 2/24/22 | 2/28/23 | 2/29/24 | - | - | - |
1USD in Million2USD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
B-
Sell
Buy
Mean consensus
BUY
Number of Analysts
11
Last Close Price
26.33
USD
Average target price
45.73
USD
Spread / Average Target
+73.67%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -21.96% | 1.22B | |
| +25.83% | 661B | |
| +27.00% | 566B | |
| -6.76% | 352B | |
| +20.34% | 332B | |
| +3.00% | 283B | |
| +13.09% | 231B | |
| +5.46% | 200B | |
| -9.61% | 195B | |
| -6.26% | 145B |
- Stock Market
- Equities
- PCRX Stock
- Financials Pacira BioSciences, Inc.
